Woodline Partners LP Has $9.55 Million Stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Woodline Partners LP trimmed its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 72.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 77,564 shares of the specialty pharmaceutical company's stock after selling 201,644 shares during the period. Woodline Partners LP owned about 0.13% of Jazz Pharmaceuticals worth $9,552,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Bessemer Group Inc. raised its stake in shares of Jazz Pharmaceuticals by 0.3% during the fourth quarter. Bessemer Group Inc. now owns 26,932 shares of the specialty pharmaceutical company's stock worth $3,317,000 after buying an additional 92 shares during the last quarter. CIBC Asset Management Inc increased its stake in Jazz Pharmaceuticals by 5.2% in the fourth quarter. CIBC Asset Management Inc now owns 1,972 shares of the specialty pharmaceutical company's stock valued at $243,000 after purchasing an additional 97 shares in the last quarter. Synovus Financial Corp increased its stake in Jazz Pharmaceuticals by 0.5% in the fourth quarter. Synovus Financial Corp now owns 19,206 shares of the specialty pharmaceutical company's stock valued at $2,365,000 after purchasing an additional 100 shares in the last quarter. Quarry LP increased its stake in Jazz Pharmaceuticals by 6.3% in the fourth quarter. Quarry LP now owns 1,700 shares of the specialty pharmaceutical company's stock valued at $209,000 after purchasing an additional 100 shares in the last quarter. Finally, Quadrant Capital Group LLC increased its stake in Jazz Pharmaceuticals by 97.1% in the fourth quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company's stock valued at $25,000 after purchasing an additional 101 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, CAO Patricia Carr sold 4,813 shares of the stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $144.42, for a total value of $695,093.46. Following the transaction, the chief accounting officer now directly owns 8,237 shares of the company's stock, valued at $1,189,587.54. This represents a 36.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Bruce C. Cozadd sold 1,000 shares of the stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $116.35, for a total transaction of $116,350.00. Following the completion of the transaction, the chief executive officer now directly owns 439,307 shares in the company, valued at $51,113,369.45. The trade was a 0.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 28,236 shares of company stock valued at $3,956,190 over the last ninety days. 4.20% of the stock is currently owned by company insiders.

Jazz Pharmaceuticals Stock Performance

JAZZ stock traded down $1.75 during trading hours on Wednesday, reaching $107.71. The stock had a trading volume of 166,795 shares, compared to its average volume of 850,652. The stock has a market capitalization of $6.64 billion, a PE ratio of 15.18, a price-to-earnings-growth ratio of 1.04 and a beta of 0.38. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The stock has a 50-day simple moving average of $111.57 and a 200 day simple moving average of $121.78. Jazz Pharmaceuticals plc has a fifty-two week low of $95.49 and a fifty-two week high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share for the quarter, missing the consensus estimate of $4.65 by ($2.97). The company had revenue of $897.84 million during the quarter, compared to the consensus estimate of $984.16 million. Jazz Pharmaceuticals had a net margin of 11.60% and a return on equity of 29.30%. Jazz Pharmaceuticals's revenue for the quarter was down .5% compared to the same quarter last year. During the same period in the previous year, the company earned $2.68 earnings per share. Analysts predict that Jazz Pharmaceuticals plc will post 16.96 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently issued reports on JAZZ. Barclays reissued an "overweight" rating and set a $200.00 price objective (up previously from $190.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, February 27th. Piper Sandler reissued an "overweight" rating and set a $147.00 price objective (down previously from $176.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, May 7th. Needham & Company LLC reissued a "buy" rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a research report on Wednesday, May 7th. Cantor Fitzgerald cut shares of Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and increased their target price for the stock from $140.00 to $150.00 in a report on Wednesday, February 26th. Finally, Morgan Stanley reduced their target price on shares of Jazz Pharmaceuticals from $183.00 to $166.00 and set an "overweight" rating for the company in a report on Wednesday, May 7th. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $182.79.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.